$CRIS

Enovis Corp. (ENOV) insiders bought shares near a 52-week low, with CEO Damien McDonald acquiring 13,035 shares at $19.10-$19.16. Atara Biotherapeutics (ATRA) director bought 104,166 shares at $9.60. Smith-Midland Corp. (SMID) insiders also made purchases. Illumina (ILMN) director sold $57.2M in shares near a 52-week high. Caris Life Sciences (CRIS) exec sold $14.8M in shares. Okta (OKTA) CFO sold 80,000 shares. Krystal Biotech (KRY) execs sold shares near a 52-week high.

Curis, Inc. (CRIS) priced a public offering with certain healthcare-focused institutional investors for 3.733 million shares or pre-funded warrants plus warrants. Combined price is $1.50 per share, with expected gross proceeds of about $5.6 million, closing around Aug. 14, 2026. Warrants exercise at $1.75, pre-funded warrants at $0.01. CRIS focuses on Emavusertib (CA-4948).

Curis (NASDAQ:CRIS) reported progress in clinical programs for its oral IRAK4 and FLT3 inhibitor targeting blood cancers. HC Wainwright said TakeAim CLL enrollment is ahead of plan, with year-end guidance raised to 5-10 patients, and reiterated a Buy rating while lifting its price target from $17 to $43. The note also updated emavusertib valuation assumptions and shifted PCNSL launch to 2029 and AML/MDS to 2032.

Curis Inc. (NASDAQ:CRIS) reported updated clinical results for emavusertib and expanded trial timeline guidance. In its TakeAim Primary CNS Lymphoma study, overall response was 100% (5/5) in BTK-naive evaluable patients and 86% (6/7) overall. BTK-experienced response was 26% (10/39). In TakeAim CLL, Curis added sites and raised its year-end data target to 5-10 patients in Dec 2026.

Curis, Inc. (NASDAQ:CRIS) shares rose about 11% after the company reported updated emavusertib clinical data in primary CNS lymphoma and raised enrollment guidance for its chronic lymphocytic leukemia study. In PCNSL, it cited an 86% overall response rate in BTK inhibitor-naïve and 26% in BTKi-experienced patients as of July 1, 2026. For CLL, it guided year-end enrollment to 5-10 patients.

Curis Inc. (NASDAQ:CRIS) shares rose 8.51% to $0.46 after hours Wednesday after the company confirmed its previously approved reverse stock split will take effect Thursday at 5:00 p.m. ET, with split-adjusted trading starting Jul. 6. Shareholders approved a 1-for-5 to 1-for-25 split to help regain Nasdaq’s $1 bid compliance.

Curis (NASDAQ: CRIS) said 11 clinical sites are open for patient enrollment in its Phase 2 TakeAim CLL study of emavusertib plus zanubrutinib. The company reaffirmed dosing of the first five patients by end-July 2026 and expects data in December 2026. Stockholders approved a reverse stock split (1-for-5 to 1-for-25) to help regain Nasdaq bid-price compliance.

CURIS INC (CRIS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. cris-20260625 0001108205 false 0001108205 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date

Curis Inc. (CRIS) reported a significant Q1 2026 miss, with GAAP diluted EPS of -$1.25 against an estimated -$0.40, and $0 revenue compared to an estimated $1.49 million. The revenue shortfall was due to the prior sale of Erivedge royalties, while the widened net loss was primarily attributed to a non-cash warrant liability revaluation from a January 2026 PIPE financing. Despite this, the company's cash balance improved, and R&D expenses decreased, indicating disciplined cost management, though its business model remains capital-intensive.

Curis (NASDAQ: CRIS) reported a significantly wider net loss of $24.2 million in Q1 2026, up from $10.6 million in Q1 2025, with revenue dropping to zero after the sale of its Erivedge royalty stream. Despite a January 2026 PIPE financing that boosted cash to $15.0 million, the company indicated current funds are insufficient for the next 12 months and that future operations depend on additional financing, including potential Series B warrant exercises. Curis is advancing emavusertib in multiple cancer trials and expects key clinical data readouts by the end of 2026 and early 2027.